288 related articles for article (PubMed ID: 28873009)
1.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
4. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
5. [
Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
[TBL] [Abstract][Full Text] [Related]
6. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET Imaging to Assess Target Engagement: Experience from
Menke-van der Houven van Oordt CW; McGeoch A; Bergstrom M; McSherry I; Smith DA; Cleveland M; Al-Azzam W; Chen L; Verheul H; Hoekstra OS; Vugts DJ; Freedman I; Huisman M; Matheny C; van Dongen G; Zhang S
J Nucl Med; 2019 Jul; 60(7):902-909. PubMed ID: 30733323
[TBL] [Abstract][Full Text] [Related]
8. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
9. Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of
Warnders FJ; Terwisscha van Scheltinga AGT; Knuehl C; van Roy M; de Vries EFJ; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
J Nucl Med; 2017 Aug; 58(8):1210-1215. PubMed ID: 28360206
[TBL] [Abstract][Full Text] [Related]
10. Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.
Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Morandini R; Doumont G; Sherer F; Van Simaeys G; Goldman S; Ghanem G; Flamen P
Mol Imaging Biol; 2015 Oct; 17(5):697-703. PubMed ID: 25761907
[TBL] [Abstract][Full Text] [Related]
11. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
[TBL] [Abstract][Full Text] [Related]
12. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract][Full Text] [Related]
13. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
14. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
15. Imaging of HER2 with [
Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
[No Abstract] [Full Text] [Related]
16.
Bensch F; Lamberts LE; Smeenk MM; Jorritsma-Smit A; Lub-de Hooge MN; Terwisscha van Scheltinga AGT; de Jong JR; Gietema JA; Schröder CP; Thomas M; Jacob W; Abiraj K; Adessi C; Meneses-Lorente G; James I; Weisser M; Brouwers AH; de Vries EGE
Clin Cancer Res; 2017 Oct; 23(20):6128-6137. PubMed ID: 28733442
[No Abstract] [Full Text] [Related]
17. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
18. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
19. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo.
Liu H; Ruan S; Larsen ME; Tan C; Liu B; Lyu H
Biol Proced Online; 2023 Jun; 25(1):19. PubMed ID: 37370010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
